{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:20:31Z","timestamp":1791951631504,"version":"4.3.4"},"reference-count":49,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-ES013508"],"award-info":[{"award-number":["P30-ES013508"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-ES019851"],"award-info":[{"award-number":["T32-ES019851"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women. A common symptom of PCOS is hyperandrogenism (AE); however, the source of these androgens is uncertain. Aldo-keto reductase family 1 member C3 (AKR1C3) catalyzes the formation of testosterone (T) and 5\u03b1-dihydrotestosterone (DHT) in peripheral tissues, which activate the androgen receptor (AR). AKR1C3 is induced by insulin in adipocytes and may be central in driving the AE in PCOS. We elucidated the conversion of both classical and 11-oxygenated androgens to potent androgens in a model of PCOS adipocytes. Using high-performance liquid chromatography (HPLC) discontinuous kinetic assays to measure product formation by recombinant AKR1C3, we found that the conversion of 11-keto-\u03944-androstene-3,17-dione (11K-4AD) to 11-ketotestosterone (11K-T) and 11-keto-5\u03b1-androstane-3,17-dione (11K-5AD) to 11-keto-5\u03b1-dihydrotestosterone (11K-DHT) were superior to the formation of T and DHT. We utilized a stable isotope dilution liquid chromatography high resolution mass spectrometric (SID-LC-HRMS) assay for the quantification of both classical and 11-oxygenated androgens in differentiated Simpson-Golabi-Behmel syndrome adipocytes in which AKR1C3 was induced by insulin. Adipocytes were treated with adrenal derived 11\u03b2-hydroxy-\u03944-androstene-3,17-dione (11\u03b2-OH-4AD), 11K-4AD, or \u03944-androstene-3,17-dione (4AD). The conversion of 11\u03b2-OH-4AD and 11K-4AD to 11K-T required AKR1C3. We also found that once 11K-T is formed, it is inactivated to 11\u03b2-hydroxy-testosterone (11\u03b2-OH-T) by 11\u03b2-hydroxysteroid dehydrogenase type 1 (HSD11B1). Our data reveal a unique role for HSD11B1 in protecting the AR from AE. We conclude that the 11-oxygenated androgens formed in adipocytes may contribute to the hyperandrogenic profile of PCOS women and that AKR1C3 is a potential therapeutic target to mitigate the AE of PCOS.<\/jats:p>","DOI":"10.1210\/endocr\/bqac068","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T15:57:40Z","timestamp":1652457460000},"source":"Crossref","is-referenced-by-count":60,"title":["Conversion of Classical and 11-Oxygenated Androgens by Insulin-Induced AKR1C3 in a Model of Human PCOS Adipocytes"],"prefix":"10.1210","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5735-9896","authenticated-orcid":false,"given":"Ryan D","family":"Paulukinas","sequence":"first","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics , Philadelphia, PA 19104 , USA"},{"name":"Center of Excellence in Environmental Toxicology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5117-2038","authenticated-orcid":false,"given":"Clementina A","family":"Mesaros","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics , Philadelphia, PA 19104 , USA"},{"name":"Center of Excellence in Environmental Toxicology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-1066","authenticated-orcid":false,"given":"Trevor M","family":"Penning","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics , Philadelphia, PA 19104 , USA"},{"name":"Center of Excellence in Environmental Toxicology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"issue":"9","key":"2022060617395007800_CIT0001","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/humrep\/dey256","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"33","author":"Teede","year":"2018","journal-title":"Hum Reprod."},{"issue":"1-2","key":"2022060617395007800_CIT0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0303-7207(98)00178-6","article-title":"Genetics of polycystic ovary syndrome","volume":"145","author":"Franks","year":"1998","journal-title":"Mol Cell Endocrinol."},{"issue":"11","key":"2022060617395007800_CIT0003","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4158\/EP15748.DSC","article-title":"American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the best practice in the evaluation and treatment of polycystic ovarian syndrome--Part 1","volume":"21","author":"Goodman","year":"2015","journal-title":"Endocr Pract."},{"issue":"3","key":"2022060617395007800_CIT0004","doi-asserted-by":"crossref","first-page":"e1071","DOI":"10.1210\/clinem\/dgaa839","article-title":"Update on PCOS: consequences, challenges, and guiding treatment","volume":"106","author":"Hoeger","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"1-6","key":"2022060617395007800_CIT0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0960-0760(99)00044-8","article-title":"Polycystic ovary syndrome: evidence for a primary disorder of ovarian steroidogenesis","volume":"69","author":"Franks","year":"1999","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"6","key":"2022060617395007800_CIT0006","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0010-7824(90)90002-D","article-title":"Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome","volume":"42","author":"Falsetti","year":"1990","journal-title":"Contraception."},{"issue":"1","key":"2022060617395007800_CIT0007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/00016349509009945","article-title":"Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome","volume":"74","author":"Falsetti","year":"1995","journal-title":"Acta Obstet Gynecol Scand."},{"issue":"1","key":"2022060617395007800_CIT0008","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/humrep\/deq301","article-title":"The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies","volume":"26","author":"Halperin","year":"2011","journal-title":"Hum Reprod."},{"issue":"3","key":"2022060617395007800_CIT0009","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0010-7824(96)00006-6","article-title":"Changes in androgens during treatment with four low-dose contraceptives","volume":"53","author":"Coenen","year":"1996","journal-title":"Contraception."},{"key":"2022060617395007800_CIT0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mce.2018.07.002","article-title":"AKR1C3 (type 5 17beta-hydroxysteroid dehydrogenase\/prostaglandin F synthase): Roles in malignancy and endocrine disorders","volume":"489","author":"Penning","year":"2019","journal-title":"Mol Cell Endocrinol."},{"issue":"2","key":"2022060617395007800_CIT0011","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/er.2018-00089","article-title":"Structural and functional biology of aldo-keto reductase steroid-transforming enzymes","volume":"40","author":"Penning","year":"2019","journal-title":"Endocr Rev."},{"key":"2022060617395007800_CIT0012","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jsbmb.2018.06.013","article-title":"11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer","volume":"183","author":"Barnard","year":"2018","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"1-2","key":"2022060617395007800_CIT0013","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mce.2013.07.006","article-title":"11beta-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?","volume":"377","author":"Storbeck","year":"2013","journal-title":"Mol Cell Endocrinol."},{"issue":"7","key":"2022060617395007800_CIT0014","doi-asserted-by":"crossref","first-page":"e0159867e0159867","DOI":"10.1371\/journal.pone.0159867","article-title":"11-Ketotestosterone and 11-ketodihydrotestosterone in castration resistant prostate cancer: potent androgens which can no longer be ignored","volume":"11","author":"Pretorius","year":"2016","journal-title":"PLoS One."},{"issue":"1","key":"2022060617395007800_CIT0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/JOE-18-0674","article-title":"Excess androgen production in subcutaneous adipose tissue of women with polycystic ovarian syndrome is not related to insulin or LH","volume":"241","author":"Amer","year":"2019","journal-title":"J Endocrinol."},{"issue":"9","key":"2022060617395007800_CIT0016","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1210\/jc.2017-00947","article-title":"AKR1C3-Mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome","volume":"102","author":"O\u2019Reilly","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"2022060617395007800_CIT0017","doi-asserted-by":"crossref","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","article-title":"Polycystic ovary syndrome","volume":"2","author":"Azziz","year":"2016","journal-title":"Nat Rev Dis Primers."},{"issue":"3","key":"2022060617395007800_CIT0018","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1210\/jc.2012-2912","article-title":"Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation","volume":"98","author":"Rege","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022060617395007800_CIT0019","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/acta.0.0720545","article-title":"Biosynthesis of 11 beta-hydroxyandrostenedione by human and baboon adrenals","volume":"72","author":"Axelrod","year":"1973","journal-title":"Acta Endocrinol."},{"key":"2022060617395007800_CIT0020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jsbmb.2013.04.010","article-title":"11beta-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5alpha-reductase yielding 11beta-hydroxy-5alpha-androstanedione","volume":"138","author":"Swart","year":"2013","journal-title":"J Steroid Biochem Mol Biol."},{"key":"2022060617395007800_CIT0021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jsbmb.2019.02.013","article-title":"The 11\u03b2-hydroxysteroid dehydrogenase isoforms: pivotal catalytic activities yield potent C11-oxy C(19) steroids with 11\u03b2HSD2 favouring 11-ketotestosterone, 11-ketoandrostenedione and 11-ketoprogesterone biosynthesis","volume":"189","author":"Gent","year":"2019","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"3","key":"2022060617395007800_CIT0022","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1210\/jc.2016-3285","article-title":"11-oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome","volume":"102","author":"O\u2019Reilly","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2022060617395007800_CIT0023","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1507\/endocrj.EJ18-0212","article-title":"11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome","volume":"65","author":"Yoshida","year":"2018","journal-title":"Endocr J."},{"issue":"11","key":"2022060617395007800_CIT0024","doi-asserted-by":"crossref","first-page":"e3903","DOI":"10.1210\/clinem\/dgaa532","article-title":"11-oxygenated C19 steroids do not distinguish the hyperandrogenic phenotype of PCOS daughters from girls with obesity","volume":"105","author":"Torchen","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022060617395007800_CIT0025","doi-asserted-by":"crossref","first-page":"e2047","DOI":"10.1210\/clinem\/dgab920","article-title":"Clinical value of serum levels of 11-oxygenated metabolites of testosterone in women with polycystic ovary syndrome","volume":"107","author":"Tosi","year":"2022","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022060617395007800_CIT0026","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1021\/jm201547v","article-title":"Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships","volume":"55","author":"Adeniji","year":"2012","journal-title":"J Med Chem."},{"key":"2022060617395007800_CIT0027","doi-asserted-by":"crossref","first-page":"105283105283","DOI":"10.1016\/j.jsbmb.2019.01.001","article-title":"A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics","volume":"192","author":"Wangtrakuldee","year":"2019","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"19","key":"2022060617395007800_CIT0028","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.1021\/bi972725u","article-title":"Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione","volume":"37","author":"Burczynski","year":"1998","journal-title":"Biochemistry."},{"issue":"16","key":"2022060617395007800_CIT0029","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1021\/acs.jmedchem.6b00160","article-title":"Discovery of (R)-2-(6-methoxynaphthalen-2-yl)butanoic acid as a potent and selective aldo-keto reductase 1C3 inhibitor","volume":"59","author":"Adeniji","year":"2016","journal-title":"J Med Chem."},{"issue":"Pt 1","key":"2022060617395007800_CIT0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/bj3510067","article-title":"Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones","volume":"351","author":"Penning","year":"2000","journal-title":"Biochem J."},{"issue":"1","key":"2022060617395007800_CIT0031","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0009-8981(67)90099-X","article-title":"Estimation of ketosteroids with 2,4-dinitrophenylhydrazine. Determination of dehydroepiandrosterone, androsterone and etiocholanolone in urine","volume":"17","author":"Treiber","year":"1967","journal-title":"Clin Chim Acta"},{"key":"2022060617395007800_CIT0032","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ab.2014.04.034","article-title":"Simplified 2,4-dinitrophenylhydrazine spectrophotometric assay for quantification of carbonyls in oxidized proteins","volume":"458","author":"Mesquita","year":"2014","journal-title":"Anal Biochem."},{"issue":"4","key":"2022060617395007800_CIT0033","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000145784","article-title":"Human SGBS cells - a unique tool for studies of human fat cell biology","volume":"1","author":"Fischer-Posovszky","year":"2008","journal-title":"Obes Facts."},{"issue":"12","key":"2022060617395007800_CIT0034","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1210\/en.2006-0627","article-title":"Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer","volume":"147","author":"Bauman","year":"2006","journal-title":"Endocrinology."},{"issue":"13-14","key":"2022060617395007800_CIT0035","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.steroids.2004.09.014","article-title":"Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase\/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate","volume":"69","author":"Lin","year":"2004","journal-title":"Steroids."},{"key":"2022060617395007800_CIT0036","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.steroids.2016.10.003","article-title":"Validation of highly sensitive simultaneous targeted and untargeted analysis of keto-steroids by Girard P derivatization and stable isotope dilution-liquid chromatography-high resolution mass spectrometry","volume":"116","author":"Frey","year":"2016","journal-title":"Steroids."},{"key":"2022060617395007800_CIT0037","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jsbmb.2013.06.014","article-title":"Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization\/selected reaction monitoring\/mass spectrometry (SID-LC\/ESI\/SRM\/MS) method for quantification of keto-androgens in human serum","volume":"138","author":"Tamae","year":"2013","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"Pt B","key":"2022060617395007800_CIT0038","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jsbmb.2016.08.001","article-title":"Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry","volume":"165","author":"Zang","year":"2017","journal-title":"J Steroid Biochem Mol Biol."},{"key":"2022060617395007800_CIT0039","doi-asserted-by":"crossref","volume-title":"Conversion of Classical and 11-oxygenated Androgens by Insulin Induced AKR1C3 in a Model of Human PCOS adipocytes: Supplemental Figure S1. Figshare.","author":"Paulukinas","DOI":"10.1210\/endocr\/bqac068"},{"key":"2022060617395007800_CIT0040","article-title":"Conversion of Classical and 11-oxygenated androgens by insulin induced AKR1C3 in a Model of Human PCOS adipocytes: Supplemental Figure S2. Figshare.","author":"Paulukinas"},{"key":"2022060617395007800_CIT0041","doi-asserted-by":"crossref","volume-title":"Conversion of classical and 11-oxygenated androgens by insulin induced AKR1C3 in a model of human PCOS adipocytes: Supplemental Figure S3. Figshare.","author":"Paulukinas","DOI":"10.1210\/endocr\/bqac068"},{"issue":"5","key":"2022060617395007800_CIT0042","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.bmcl.2011.01.010","article-title":"Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17\u03b2-hydroxysteroid dehydrogenase (AKR1C3)","volume":"21","author":"Adeniji","year":"2011","journal-title":"Bioorg Med Chem Lett."},{"issue":"5","key":"2022060617395007800_CIT0043","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10637-014-0130-5","article-title":"In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17\u03b2-hydroxysteroid dehydrogenase type 5 (17\u03b2HSD5; AKR1C3)","volume":"32","author":"Kikuchi","year":"2014","journal-title":"Invest New Drugs."},{"issue":"2","key":"2022060617395007800_CIT0044","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.bcp.2007.09.008","article-title":"An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies","volume":"75","author":"Byrns","year":"2008","journal-title":"Biochem Pharmacol."},{"issue":"5","key":"2022060617395007800_CIT0045","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1210\/er.2003-0031","article-title":"11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response","volume":"25","author":"Tomlinson","year":"2004","journal-title":"Endocr Rev."},{"issue":"18","key":"2022060617395007800_CIT0046","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1021\/jm025530f","article-title":"Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs: Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1","volume":"45","author":"Barf","year":"2002","journal-title":"J Med Chem."},{"key":"2022060617395007800_CIT0047","article-title":"Conversion of classical and 11-oxygenated androgens by insulin induced AKR1C3 in a model of human PCOS adipocytes: Supplemental Figure S4. Figshare.","author":"Paulukinas"},{"issue":"7","key":"2022060617395007800_CIT0048","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/EC-19-0549","article-title":"Androstenedione changes steroidogenic activity of SGBS cells","volume":"9","author":"Ernst","year":"2020","journal-title":"Endocr Connect."},{"issue":"3","key":"2022060617395007800_CIT0049","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/eje.0.1490163","article-title":"Tissue-specific Cushing\u2019s syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action","volume":"149","author":"Stewart","year":"2003","journal-title":"Eur J Endocrinol."}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqac068\/43704578\/bqac068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/163\/7\/bqac068\/43964460\/bqac068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/163\/7\/bqac068\/43964460\/bqac068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T17:40:37Z","timestamp":1654537237000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqac068\/6585535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqac068","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,5,13]]},"article-number":"bqac068"}}